European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27349614.
- Also identified by DOI 10.1016/j.eururo.2016.06.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.
Medical subject headings
- Anilides
- Antibodies, Monoclonal
- Carcinoma, Renal Cell
- Pyridines